PE20010478A1 - Usos y composiciones de inhibidores de fosfodiesterasa tipo 5 del 3`,5'-guanosinmonofosfato ciclico para el tratamiento de enfermedades y condiciones del ojo - Google Patents
Usos y composiciones de inhibidores de fosfodiesterasa tipo 5 del 3`,5'-guanosinmonofosfato ciclico para el tratamiento de enfermedades y condiciones del ojoInfo
- Publication number
- PE20010478A1 PE20010478A1 PE2000000736A PE0007362000A PE20010478A1 PE 20010478 A1 PE20010478 A1 PE 20010478A1 PE 2000000736 A PE2000000736 A PE 2000000736A PE 0007362000 A PE0007362000 A PE 0007362000A PE 20010478 A1 PE20010478 A1 PE 20010478A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- guanosinmonophosphate
- cyclic
- treatment
- ona
- Prior art date
Links
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title abstract 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 PURINE COMPOUND Chemical group 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010061323 Optic neuropathy Diseases 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000020911 optic nerve disease Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE AL USO DE UN COMPUESTO DE PURINA SUSTITUIDO DE FORMULA I, DONDE: R1 ES H, ALQUILO C1-C3, CICLOALQUILO C3-C5, PERFLUOROALQUILO; R2 ES H, ALQUILO C1-C6; R3 ES ALQUILO C1-C6, ALQUENILO C3-C6, ALQUINILO C3-C6, ENTRE OTROS; R4 JUNTO CON N FORMAN UN PIRROLIDINILO, PIPERIDINO, ENTRE OTROS; R5 ES H, ALQUILO C1-C4, ALCOXI C1-C3, NR7R8, CONR7R8; R6 ES H, ALQUILO C1-C6, HIDROXIALQUILO C2-C6, (R7R8N)-ALQUILO C2-C6, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 5-[2-ALILOXI-5-(4-METILPIPERAZINILSULFONIL)FENIL]-1-METIL-3-n-PROPIL-1,6-DIHIDRO-7H-PIRAZOLO[4,3-d]PIRIMIDIN-7-ONA; 5-[2-ETOXI-5-[PIPERAZINILSULFONIL)FENIL]-1-METIL-3-n-PROPIL-1,6-DIHIDRO-7H-PIRAZOLO-[4,3-d]PIRIMIDIN-7-ONA, CITRATO DE 5-[2-ETOXI-5-(4-METILPIPERAZINILSULFONIL)FENIL]-1-METIL-3n-PROPIL-1,6-DIHIDRO-7H-PIRAZOLO[4,3-d]PIRIMIDIN-7-ONA, ENTRE OTROS; UTILIZANDOSE DE 5 mg/DIA HASTA 250mg/DIA. EL COMPUESTO DE FORMULA I ES UN INHIBIDOR DE LA FOSFODIESTERASA TIPO 5 DEL 3`,5'-GUANOSINMONOFOSFATO CICLICO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA OCLUSION DE LA ARTERIA CENTRAL DE LA RETINA; PRESION INTRAOCULAR ELEVADO, NEUROPATIA OPTICA TAL COMO ISQUEMICA ANTERIOR, GLAUCOMA, DEGENERACION MACULAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14609599P | 1999-07-28 | 1999-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010478A1 true PE20010478A1 (es) | 2001-04-20 |
Family
ID=22515837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000736A PE20010478A1 (es) | 1999-07-28 | 2000-07-21 | Usos y composiciones de inhibidores de fosfodiesterasa tipo 5 del 3`,5'-guanosinmonofosfato ciclico para el tratamiento de enfermedades y condiciones del ojo |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20020119974A1 (es) |
| EP (1) | EP1074258A3 (es) |
| JP (1) | JP2001048788A (es) |
| KR (1) | KR20010066966A (es) |
| AU (1) | AU768750B2 (es) |
| CA (1) | CA2314571C (es) |
| CO (1) | CO5200847A1 (es) |
| HU (1) | HUP0002963A3 (es) |
| IL (1) | IL137429A0 (es) |
| PE (1) | PE20010478A1 (es) |
| ZA (1) | ZA200003768B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| WO2001026659A1 (de) * | 1999-10-12 | 2001-04-19 | Lareida Juerg | Arzneimittel zur behandlung von neuropathien |
| IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| US7816399B2 (en) * | 2001-04-19 | 2010-10-19 | Teika Pharmaceutical Co., Ltd. | Medicines and medicinal kits |
| US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| DE10224462A1 (de) * | 2002-06-03 | 2003-12-11 | Bayer Ag | Verwendung von cGMP stimulierenden Verbindungen |
| DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
| DE10232113A1 (de) | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
| JP2007517210A (ja) * | 2003-12-24 | 2007-06-28 | ファイザー・プロダクツ・インク | 網膜毒性のスクリーニング法 |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| DE102005009240A1 (de) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
| US9254287B2 (en) | 2012-06-11 | 2016-02-09 | Macuclear, Inc. | Therapeutic formulation and methods of treatment |
| FR3008618A1 (fr) * | 2013-07-19 | 2015-01-23 | Univ Paris Curie | Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine |
| CA3108551A1 (en) | 2018-08-06 | 2020-02-13 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
| JP2023547441A (ja) * | 2020-11-02 | 2023-11-10 | ニコックス エス．エー． | 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤 |
| EP4233867A1 (en) | 2022-02-24 | 2023-08-30 | Nicox SA | Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5500230A (en) * | 1987-01-23 | 1996-03-19 | The General Hospital Corporation | Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators |
| SE8701258D0 (sv) * | 1987-03-26 | 1987-03-26 | Pharmacia Ab | A composition for the topical treatment of glaucoma or ocular hypertension |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| GB9315017D0 (en) * | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| DK0975347T3 (da) * | 1997-02-28 | 2008-06-16 | Nycomed Gmbh | Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister |
| JP2002509553A (ja) * | 1997-10-27 | 2002-03-26 | 藤沢薬品工業株式会社 | ｃＧＭＰ−ＰＤＥ阻害剤としての三環式化合物 |
| AU4717299A (en) * | 1998-06-26 | 2000-01-17 | Nastech Pharmaceutical Company, Inc | Nasal delivery of sildenafil citrate |
-
2000
- 2000-07-20 IL IL13742900A patent/IL137429A0/xx unknown
- 2000-07-21 EP EP00306235A patent/EP1074258A3/en not_active Withdrawn
- 2000-07-21 PE PE2000000736A patent/PE20010478A1/es not_active Application Discontinuation
- 2000-07-24 AU AU48789/00A patent/AU768750B2/en not_active Ceased
- 2000-07-24 JP JP2000222162A patent/JP2001048788A/ja active Pending
- 2000-07-26 ZA ZA200003768A patent/ZA200003768B/xx unknown
- 2000-07-26 CA CA002314571A patent/CA2314571C/en not_active Expired - Fee Related
- 2000-07-27 HU HU0002963A patent/HUP0002963A3/hu unknown
- 2000-07-27 KR KR1020000043271A patent/KR20010066966A/ko not_active Application Discontinuation
- 2000-07-28 CO CO00056997A patent/CO5200847A1/es not_active Application Discontinuation
-
2002
- 2002-04-19 US US10/126,375 patent/US20020119974A1/en not_active Abandoned
-
2005
- 2005-09-12 US US11/224,616 patent/US20060014754A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2314571C (en) | 2005-12-13 |
| EP1074258A2 (en) | 2001-02-07 |
| HUP0002963A3 (en) | 2001-09-28 |
| AU768750B2 (en) | 2004-01-08 |
| US20020119974A1 (en) | 2002-08-29 |
| AU4878900A (en) | 2001-02-01 |
| KR20010066966A (ko) | 2001-07-11 |
| JP2001048788A (ja) | 2001-02-20 |
| CA2314571A1 (en) | 2001-01-28 |
| CO5200847A1 (es) | 2002-09-27 |
| ZA200003768B (en) | 2002-03-27 |
| HU0002963D0 (en) | 2000-10-28 |
| IL137429A0 (en) | 2001-07-24 |
| US20060014754A1 (en) | 2006-01-19 |
| HUP0002963A2 (hu) | 2001-04-28 |
| EP1074258A3 (en) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010478A1 (es) | Usos y composiciones de inhibidores de fosfodiesterasa tipo 5 del 3`,5'-guanosinmonofosfato ciclico para el tratamiento de enfermedades y condiciones del ojo | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| ES2213504T1 (es) | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. | |
| ES2094843T3 (es) | Bencisotiazol- y bencisoxazol-3-carboxamidas, un procedimiento para su preparacion y su empleo como medicamentos antipsicoticos. | |
| RU2006146970A (ru) | Бициклические гетероциклы и их применение в качестве ингибиторов вич интегразы | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR002971A1 (es) | COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA. | |
| PE20020540A1 (es) | Derivados del acido benzo pirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos | |
| ATE557002T1 (de) | Verbindungen mit calcimimetischer wirkung | |
| AR033791A1 (es) | Compuestos de acidos oxamicos y derivados como ligandos de receptores tiroideos,su uso. composicion y estuche que lo contiene | |
| CO4960641A1 (es) | Derivados de piperidina 1,4-disustituida conteniendo fluor | |
| JP2012518685A5 (es) | ||
| PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
| AR040806A1 (es) | Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| PE20001037A1 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa | |
| PE10897A1 (es) | Compuestos benzo fusionados | |
| HUP0001760A2 (hu) | Aril-acil-piridazin-származékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és a vegyületek alkalmazása gyógyszerkészítmények előállítására | |
| PE20011089A1 (es) | Tioamidas de oxazolidinona con sustituyentes de piperazin-amida | |
| SE9703377D0 (sv) | New compounds | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |